ReviewNuclear medicine and molecular imaging2016
Combination Radioimmunotherapy Approaches and Quantification of Immuno-PET.
Review in Nuclear medicine and molecular imaging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Tumor microenvironment modulation by SERPINE1 increases radioimmunotherapy in murine model of gastric cancer.Scientific reports · 2025Article
- Manual Versus Artificial Intelligence-Based Segmentations as a Pre-processing Step in Whole-body PET Dosimetry Calculations.Molecular imaging and biology · 2023Article
- Diacerein, an inhibitor of IL-1β downstream mediated apoptosis, improves radioimmunotherapy in a mouse model of Burkitt's lymphoma.American journal of cancer research · 2021Article
- Theranostic Terbium Radioisotopes: Challenges in Production for Clinical Application.Frontiers in medicine · 2021Review
- Inhibition of HIF-1α by Atorvastatin DuringCancers · 2020Article
- B7-H3-targeted Radioimmunotherapy of Human Cancer.Current medicinal chemistry · 2020Review
- Combination Radioimmunotherapy Strategies for Solid Tumors.International journal of molecular sciences · 2019Review
- Improved Quantification ofDiagnostics (Basel, Switzerland) · 2019Article
- Metal-based antibody drug conjugates. Potential and challenges in their application as targeted therapies in cancer.Journal of inorganic biochemistry · 2019Review
- Measurement of Tumor Pressure and Strategies of Imaging Tumor Pressure for Radioimmunotherapy.Nuclear medicine and molecular imaging · 2019Review
- Selection Criteria for Determination of Optimal Reconstruction Method for Cu-64 Trastuzumab Dosimetry on Siemens Inveon PET Scanner.Journal of clinical medicine · 2019Article
- Trastuzumab Induced Chemobrain, Atorvastatin Rescued Chemobrain with Enhanced Anticancer Effect and without Hair Loss-Side Effect.Journal of clinical medicine · 2019Article
- The yin and yang of imaging tumor associated macrophages with PET and MRI.Theranostics · 2019Review
- Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.AJR. American journal of roentgenology · 2017Review
- Improving theranostics in pancreatic cancer.Journal of surgical oncology · 2017Review
- FDG-PET Scan: a new Paradigm for Follicular Lymphoma Management.Mediterranean journal of hematology and infectious diseases · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal antibodies (mAbs), which play a prominent role in cancer therapy, can interact with specific antigens on cancer cells, thereby enhancing the patient's immune response via various mechanisms, or mAbs can act against cell growth factors and, thereby, arrest the proliferation of tumor cells. Radionuclide-labeled mAbs, which are used in radioimmunotherapy (RIT), are effective for cancer treatment because tumor associated-mAbs linked to cytotoxic radionuclides can selectively bind to tumor antigens and release targeted cytotoxic radiation. Immunological positron emission tomography (immuno-PET), which is the combination of PET with mAb, is an attractive option for improving tumor detection and mAb quantification. However, RIT remains a challenge because of the limited delivery of mAb into tumors. The transport and uptake of mAb into tumors is slow and heterogeneous. The tumor microenvironment contributed to the limited delivery of the mAb. During the delivery process of mAb to tumor, mechanical drug resistance such as collagen distribution or physiological drug resistance such as high intestinal pressure or absence of lymphatic vessel would be the limited factor of mAb delivery to the tumor at a potentially lethal mAb concentration. When α-emitter-labeled mAbs were used, deeper penetration of α-emitter-labeled mAb inside tumors was more important because of the short range of the α emitter. Therefore, combination therapy strategies aimed at improving mAb tumor penetration and accumulation would be beneficial for maximizing their therapeutic efficacy against solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.